RE: Chapter 305 of the Acts of 2008, An Act to Promote Cost Containment, Transparency and Efficiency in the Delivery of Quality Health Care.
Dear Secretaries Bigby and O'Connell:
On behalf of the more than 1,200 members of the Biotechnology Industry Organization (BIO), we are writing with regard to the promulgation of rules for the implementation of Chapter 305 of the Acts of 2008 (SB 2863) "An Act to Control Cost Containment, Transparency and Efficiency in the Delivery of Quality Haelth Care." We appreciate the opportunity to submit comments to ensure that the implementation of Chapter 305 does not have unintended consequences on bioscience research and development within the Commonwealth.
As one of the world's leading medical centers and biotechnology industry hubs, we acknowledge the need for Massachusetts to be at the forefront of implementing policies to improve heatlh care. We are committed toworking with the Department of Health to ensure that the regulations for Chapter 305 balance the original intent of the law -disclosure of sales and marketing expenditures- do not impede or hinder bioscience research and development in the Commonwealth.